Hydroxyurea With or Without Imatinib Mesylate in Treating Patients With Recurrent or Progressive Meningioma
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as hydroxyurea, work in different ways to stop
the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed
for cell growth. It is not yet known whether hydroxyurea is more effective when given alone
or together with imatinib mesylate in treating patients with meningioma.
PURPOSE: This randomized phase II trial is studying how well hydroxyurea works compared with
giving hydroxyurea together with imatinib mesylate in treating patients with recurrent or
progressive meningioma.